
Sign up to save your podcasts
Or


The NETest is a multigene liquid biopsy measuring 51 circulating transcript profiles via RT-PCR and machine-learning algorithms to quantify neuroendocrine tumor activity on a 0 to 100 scale. Capturing programs like proliferation, somatostatin receptor expression, and epigenomic signaling, it yields superior diagnostic sensitivity (89-99%) and progression accuracy compared to chromogranin A. Clinically, it anticipates RECIST-defined recurrence months prior to imaging and stratifies post-surgical residual disease. However, variable specificity in non-NET malignancies, lack of NCCN endorsement, single-lab proprietary architecture, and absent prospective outcome-driven data currently limit its utility to adjunct surveillance rather than diagnostic screening or direct treatment selection.
The 2024 ASBMR and BHOF Task Force advocates a treat-to-target framework for osteoporosis management, using total hip bone mineral density T-score as the primary surrogate endpoint. For patients at imminent or very high fracture risk, initiating therapy with osteoanabolic agents prior to antiresorptive consolidation yields superior bone mineral density gains and fracture reduction compared to standard sequential bisphosphonates, which blunt subsequent anabolic efficacy. Clinicians must navigate denosumab discontinuation rebound through planned antiresorptive transitions, address insurance step therapy barriers, and leverage fracture liaison services to mitigate the alarming secondary prevention treatment gap following fragility fractures.
Long-term methimazole continuation beyond the standard 12 to 18-month regimen addresses persistent autoimmune activation in high-risk Graves disease, where relapse rates exceed 70%. Thyrotropin-receptor antibody trajectories—classified as smooth, fluctuating, or smoldering—dictate immunologic burnout. Extending therapy to 60 months or longer reduces relapse to under 20% by maintaining low-dose enzymatic blockade of thyroid peroxidase. Crucially, major thionamide adverse events, including agranulocytosis, cluster within the first 90 days of initiation, making long-term maintenance doses of 2.5 to 7.5 mg daily a safe alternative to radioiodine ablation or surgery, particularly in patients with orbitopathy.
Parathyroid hormone (PTH) is an 84-amino acid peptide that maintains serum ionized calcium within a tight physiological range through an inverse sigmoidal feedback loop governed by the calcium-sensing receptor (CaSR) on chief cells. Secretion operates across three temporal scales: immediate exocytosis of preformed granules, intermediate upregulation of PTH mRNA transcription, and chronic glandular hyperplasia. Active 1,25-dihydroxyvitamin D directly suppresses PTH synthesis, whereas indirect stimulation occurs via elevated serum phosphate. Crucially, severe hypomagnesemia paradoxically impairs PTH secretion by blunting stimulus-secretion coupling, creating functional hypoparathyroidism.
Hungry bone syndrome presents as severe, prolonged hypocalcemia following parathyroidectomy for primary or secondary hyperparathyroidism, driven by the abrupt withdrawal of elevated PTH and accelerated skeletal remineralization. Definitive clinical management requires aggressive dual-route calcium repletion, combining continuous intravenous calcium gluconate for acute symptomatic crisis with high-dose oral elemental calcium up to 6 to 12 grams daily. High-dose calcitriol at 0.5 to 1.0 micrograms twice daily is critical to maximize active intestinal calcium transport. Concomitant correction of hypomagnesemia is mandatory, as magnesium deficiency impairs residual parathyroid function and induces calcitriol resistance. Titration requires frequent biochemical monitoring, with gradual weaning extending over weeks to months as bone turnover normalizes.
This episode details the historic journey toward the discovery of insulin, transitioning from a period when a Type 1 diabetes diagnosis was an inevitable death sentence to a new era of medical management. It follows the collaborative yet often volatile efforts of Frederick Banting, Charles Best, J.J.R. Macleod, and James Collip, who successfully isolated the life-saving hormone at the University of Toronto in the early 1920s. The narrative emphasizes the critical evolution of their work, moving from Banting's initial surgical hypothesis involving canine subjects to the biochemical purification necessary for human treatment. The text also highlights the group's humanitarian ethics in patenting the discovery for only three dollars to ensure global accessibility. Furthermore, it addresses the Nobel Prize controversy and internal disputes that complicated the team's legacy for decades. Finally, the overview connects these early breakthroughs to modern advancements like recombinant DNA technology and automated delivery systems, underscoring the profound lasting impact of their research.
This podcast covers the influential career of Jean-Martin Charcot, the nineteenth-century physician who founded modern clinical neurology at the Salpêtrière hospital in Paris. By applying a rigorous anatomoclinical method, Charcot successfully identified and mapped various conditions, including Multiple Sclerosis, ALS, and Parkinson’s disease. The narrative details his transition from a master of physical pathology to a pioneer in the study of hysteria and hypnosis, which laid the intellectual groundwork for psychoanalysis. While his neurological discoveries remain medical cornerstones, his work on psychological disorders is presented as a complex mixture of brilliant insight and institutional bias. Ultimately, the source portrays Charcot as a transformative figure who elevated the observation of symptoms into a precise scientific discipline.
This episode compares normocalcemic and hyperparathyroidism and idiopathic hypercalciuria, two primary drivers of hypercalciuria and nephrolithiasis. We contrast primary hyperparathyroidism, an autonomous parathyroid oversecretion causing elevated parathyroid hormone and true hypercalcemia, with idiopathic hypercalciuria, where serum calcium remains strictly normal despite excessive urinary calcium excretion.
This episode reviews the diagnostic strategies for parathyroid localization in primary hyperparathyroidism, guiding the practicing endocrinologist through the selection of optimal imaging modalities. We compare the utility of standard ultrasound and technetium-99m sestamibi scintigraphy with the high sensitivity of modern four-dimensional computed tomography scans. Finally, we discuss how accurate preoperative mapping minimizes operative times and enables focused, minimally invasive parathyroidectomy, translating complex anatomical imaging into successful surgical outcomes at the bedside.
This episode breaks down the intricacies of ICD-10 coding for type 2 diabetes mellitus, providing a practical framework for the practicing endocrinologist. We review the essential code structures under the E11 category, emphasizing the critical need to document specific manifestations, secondary complications, and long-term insulin use.
From the publisher's feed